Pacira BioSciences, Inc. (PCRX)

Market Cap	1.52B
Revenue (ttm)	669.23M
Net Income (ttm)	-4.57M
Shares Out	49.65M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	8.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	738,365
Open	31.12
Previous Close	30.85
Day's Range	30.43 - 31.12
52-Week Range	30.43 - 58.10
Beta	0.70
Analysts	Strong Buy
Price Target	57.33 (+86.86%)
Earnings Date	Nov 2, 2023

About PCRX

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsula...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 715
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX

Financial Performance

In 2022, PCRX's revenue was $666.82 million, an increase of 23.14% compared to the previous year's $541.53 million. Earnings were $15.91 million, a decrease of -62.10%.

Analyst Forecast

According to 9 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $57.33, which is an increase of 86.86% from the latest price.

Price Target

$57.33

(86.86% upside)

Analyst Consensus: Strong Buy